Blauhut B, Kramar H, Vinazzer H, Bergmann H
Thromb Res. 1985 Jul 1;39(1):81-9. doi: 10.1016/0049-3848(85)90123-9.
In 51 shock patients with DIC Antithrombin III (AT III) substitution, heparin or a combination of both substances respectively was administered. In the two groups which had been given AT III substitution the concentration of AT III rose considerably higher than the activity. There was a drop of the platelet count in both groups which had received heparin. C1 esterase inhibitor was diminished in the beginning but spontaneously increased in all groups. This increase was slowest in the group without substitution of AT III. The blood loss in cases of traumatic shock was considerably higher in the group which had received both substances. The consumption of AT III concentrates was slightly higher in the combined therapy group than in the AT III group. The duration of symptoms of DIC was considerably shorter in the two substituted groups than in the heparin group. It is concluded that additional administration of heparin does not improve the effect of AT III substitution in patients with DIC and that side effects such as thrombocytopenia and an increased blood loss are likely to develop when both substances are given simultaneously.
在51例患有弥散性血管内凝血(DIC)的休克患者中,分别给予抗凝血酶III(AT III)替代治疗、肝素治疗或两者联合治疗。在接受AT III替代治疗的两组中,AT III的浓度升高幅度明显高于活性。接受肝素治疗的两组血小板计数均下降。C1酯酶抑制剂在开始时减少,但在所有组中均自发增加。在未进行AT III替代治疗的组中,这种增加最为缓慢。在接受两种药物治疗的组中,创伤性休克患者的失血量明显更高。联合治疗组中AT III浓缩物的消耗量略高于AT III组。两个替代治疗组中DIC症状的持续时间明显短于肝素组。结论是,额外给予肝素并不能改善DIC患者AT III替代治疗的效果,并且当同时给予两种药物时,可能会出现血小板减少和失血量增加等副作用。